Oligoarticular Juvenile Idiopathic Arthritis clinical trials at UCSF
1 research study open to eligible people
open to eligible people ages 2-16
This is a research study to test whether a once-weekly injection of abatacept will prevent the progression of Juvenile Idiopathic Arthritis (JIA) to a more severe form. To evaluate the effectiveness of a 24-week course of treatment with abatacept plus usual care versus usual care to prevent polyarthritis (≥5 joints), uveitis, or treatment with other systemic medication within 18 months of randomization in children with recent-onset limited JIA.
San Francisco, California and other locations